Targeting astrocytes with viral gene therapy for alzheimer’s disease

Zachary P. Rosenthal, Andrew W. Kraft, Leah Czerniewski, Jin Moo Lee

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Alzheimer’s disease (AD), the leading cause of dementia worldwide, results from the accumulation of amyloid plaques within the brain parenchyma and the formation of neurofibrillary tangles within degenerating neurons. While neuronal degeneration is the major consequence of the disease, leading to memory loss, cognitive decline, and eventual death, other cell types within the central nervous system contribute to disease pathogenesis. In this chapter, we examine the essential role of astrocytes in normal brain physiology and in AD pathogenesis. Furthermore, we explore astrocyte-specific mechanisms that provide potential targets for intervention with novel viral gene transfer technologies that provide specific and efficient astrocyte transduction. Finally, we review several preclinical studies that illustrate the possibility that astrocytes can be selectively targeted to attenuate and potentially reverse disease progression.

Original languageEnglish
Title of host publicationGene Therapy in Neurological Disorders
PublisherElsevier
Pages97-138
Number of pages42
ISBN (Electronic)9780128098134
ISBN (Print)9780128098219
DOIs
StatePublished - Jan 1 2018

Keywords

  • Adenovirus-associated virus
  • Alzheimer’s disease (AD)
  • Astrocyte
  • Inflammation
  • Lentivirus
  • Reactive astrocytosis
  • Viral gene transfer

Fingerprint

Dive into the research topics of 'Targeting astrocytes with viral gene therapy for alzheimer’s disease'. Together they form a unique fingerprint.

Cite this